

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Hauptmann et al.

Appl. No. 08/249,671

Filed: May 26, 1994

For: Process for Preparing and

Purifying Alpha-Interferon

Art Unit: 1812

Examiner: Fitzgerald, D.

Atty. Docket: 0652.1350000/RWE/LLK

230. \$6 GP 1812

First Supplemental Information Disclosure Statement

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

DEC n 2 1993

GROUP 1800

Submitted herewith on Form PTO-1449 is a listing of documents known to the Applicants in compliance with the requirements of 37 C.F.R. § 1.56. A copy of the document is also being submitted herewith. The numbering on this **First** Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed on **December 8, 1995** in connection with the above-captioned application. In accordance with 37 C.F.R. § 1.97(c), fee payment under 37 C.F.R. § 1.17(p) is provided in our accompanying Check No. <u>18044</u>.

Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the present application.

This statement should not be construed as a representation that more material information does not exist or that an exhaustive search of the relevant art has been made.

010 UT 11/26/96 0B249671

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Robert W. Esmond Attorney for Applicants

Kobutw. Somend

Registration No. 32,893

Date: NW. 18, 1996

1100 New York Avenue, N.W. Suite 600 Washington, D.C. 20005 (202) 371-2600

RWE/mmm